INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is a major health problem and is currently ranked third for both cancer incidence and mortality \[[@R1]\]. In spite of the revised treatment patterns, CRC remains a major cause of cancer mortality. At an estimated 1.2 million new cancer cases and 608,700 deaths worldwide each year, people who die from CRC account for 8% of all cancer related deaths \[[@R2]\]. The incidence rate of CRC has been increasing greatly in China in the past few years, which accounts for about 6.5% of total cancers in urban areas and 4.6% in rural areas \[[@R3]\]. CRC is a multifactorial disease, involving the complex interactions between environmental and genetic factors \[[@R4]\]. However, the exact mechanisms which result in the development of colorectal cancer remain unclear. Nowadays, a large number of candidate genes responsible for the genesis of colorectal cancer have been identified.

Recently, the associations between vitamin D and colorectal cancer has aroused a great deal of attention, and genetic variation in metabolic pathways for these nutrients may play a role in colorectal carcinogenesis \[[@R5]\]. It's known to us that Vitamin D plays an important role in calcium absorption, cellular proliferation and differentiation, as well as carcinogenesis. Animal studies and case--control studies in humans have provided strong evidence that vitamin D protects against colorectal cancer \[[@R6], [@R7]\]. Genomic actions of the active metabolite of vitamin D \[1, 25(OH)~2~D~3~\] are mediated by the vitamin D receptor (VDR) which maps to a region on chromosome 12 \[[@R8], [@R9]\]. The active form of vitamin D \[1,25(OH)~2~D~3~\] is bound by the intracellular *VDR*. This complex bindings and interactions with target-cell nuclei (at *VDR* elements) produce varieties of biological effects \[[@R10]\]. Recently, the *VDR* gene polymorphisms \[[@R11]--[@R49]\] including *FokI* \[[@R12], [@R13], [@R15], [@R18], [@R19], [@R21]--[@R26], [@R29]--[@R32], [@R35]--[@R39], [@R41]--[@R43], [@R45]--[@R47], [@R49]\], *BsmI* \[[@R11]--[@R13], [@R15]--[@R18], [@R20], [@R23], [@R26], [@R27], [@R29], [@R30], [@R32], [@R33], [@R36], [@R37], [@R40]--[@R42], [@R44], [@R48], [@R49]\], *ApaI* \[[@R11]--[@R13], [@R15], [@R16], [@R18], [@R23], [@R27], [@R28], [@R30], [@R36], [@R41]\], *TaqI* \[[@R12]--[@R15], [@R17], [@R18], [@R20]--[@R24], [@R27], [@R28], [@R31], [@R36], [@R38], [@R41], [@R49]\] and *Cdx2* \[[@R21], [@R30], [@R31], [@R36]\] have been assessed in genetic associations studies of CRC, but the results from these studies are still inconsistent. Three meta-analyses \[[@R3], [@R50], [@R51]\] had been published assessing the associations between *VDR* polymorphisms and CRC risk in recent years. However, there are some limitations in the three studies, such as relatively small sample size. Moreover, a number of studies that assessed the associations between *VDR* polymorphisms and CRC risk were published after that period. In order to derive a more comprehensive estimation of the associations between *VDR* polymorphisms and CRC risk, we conducted a meta-analysis from 39 eligible case-control studies to evaluate the associations.

RESULTS {#s2}
=======

Data source {#s2_1}
-----------

Figure [1](#F1){ref-type="fig"} summarizes the selection process of study. According to the strategy, 139 published studies relevant to the *VDR* genes and the risk of CRC were reviewed including 28 from The Web of Science; 96 from PubMed; five from CBM and 10 from CNKI. 52 articles were selected for full-text review on the basis of their titles and abstracts. Finally, 39 articles met all inclusion criteria and were included in the meta-analysis including 22101 CRC cases and 23696 healthy controls. The 39 articles \[[@R11]--[@R49]\] consisted of five *VDR* gene polymorphisms including *FokI* \[[@R12], [@R13], [@R15], [@R18], [@R19], [@R21]--[@R26], [@R29]--[@R32], [@R34]--[@R39], [@R41]--[@R43], [@R45]--[@R47], [@R49]\], *BsmI* \[[@R11]--[@R13], [@R15]--[@R18], [@R20], [@R23], [@R26], [@R27], [@R29], [@R30], [@R32], [@R33], [@R36], [@R37], [@R40]--[@R42], [@R44], [@R48], [@R49]\], *ApaI* \[[@R11]--[@R13], [@R15], [@R16], [@R18], [@R23], [@R27], [@R28], [@R30], [@R36], [@R41]\], *TaqI* \[[@R12]--[@R15], [@R17], [@R18], [@R20]--[@R24], [@R27], [@R28], [@R31], [@R36], [@R38], [@R41], [@R49]\] and *Cdx2* \[[@R21], [@R30], [@R31], [@R36]\]. Selected characteristics on the relationships between *VDR* polymorphisms and CRC were listed in Table [1](#T1){ref-type="table"}.

![Flow diagram of the study selection process](oncotarget-09-13068-g001){#F1}

###### Characteristics of individual studies included in meta-analysis

  First Author                Year   Country          Ethnicity          Case/ Control   age             Control Methods   HWE          VDR polymorphisms   
  --------------------------- ------ ---------------- ------------------ --------------- --------------- ----------------- ------------ ------------------- ------------------------------
  Vigidal \[[@R11]\]          2016   Brazil           Caucasian          152/321         62.8 ± 13.02    62.7 ± 10.42      PCR-RFLP     Yes                 BsmI, AapI
  Alkhayal \[[@R12]\]         2016   Saudi Arabia     Caucasian          100/100         57.5 (20--80)   57.5 (21--81)     PCR          No                  FokI, BsmI, AapI, TaqI
  Takeshige \[[@R13]\]        2015   Japan            Asian              685/778         60.2 ± 9.1      58.6 ± 10.7       PCR-RFLP     Yes                 FokI, BsmI, AapI, TaqI
  Atoum \[[@R14]\]            2014   Jordan           Asian              93/102          NA              NA                PCR          Yes                 TaqI
  Laczmanska \[[@R15]\]       2014   Poland           Caucasian          179/180         65.7 (32--87)   NA                PCR          No                  FokI, BsmI, AapI, TaqI
  Rasool \[[@R16]\]           2014   India            Asian              180/188         52.05           51.06             PCR-RFLP     No                  BsmI, AapI
  Pibiri \[[@R17]\]           2014   United States    African American   961/838         62.0 ± 10       65.0 ± 6          PCR          Yes                 BsmI, TaqI
  Sarkissyan \[[@R18]\]       2014   American         Mixed              78/230          55.2 ± 9.9      54.9 ± 9.8        PCR-RFLP     Yes                 FokI, BsmI, AapI, TaqI
  Rasool \[[@R19]\]           2013   India            Asian              312/305         52.05           51.06             PCR          Yes                 FokI
  Gunduz \[[@R20]\]           2012   Turkey           Caucasian          43/42           54.8            48.8              PCR-RFLP     No                  BsmI, TaqI
  Bentley \[[@R21]\]          2102   New Zealand      Asian              200/200         69.5 ± 0.4      69.5 ± 0.4        Taqman       Yes                 FokI, TaqI, Cdx2
  Yamaji \[[@R22]\]           2012   Japan            Asian              684/641         NA              NA                Taqman       Yes                 FokI, TaqI
  Kupfer \[[@R23]\]           2011   United States    Mixed              2119/1975       64.5 ± 11.7     62.3 ± 13.2       Taqman       Yes                 FokI, BsmI, AapI, TaqI
  Ashktorab \[[@R24]\]        2011   United States    Caucasian          93/187          59              60                PCR          Yes                 FokI, TaqI
  Abulí \[[@R25]\]            2011   Spain            Caucasian          515/515         NA              NA                Taqman       Yes                 FokI
  Mahmoudi \[[@R26]\]         2010   Iran             Asian              452/452         44.3 ± 17.2     53.7 ± 13.3       PCR-RFLP     Yes                 FokI, BsmI
  Hughes \[[@R27]\]           2010   Czech Republic   Caucasian          754/627         61 (27--85)     53 (29--91)       ASM-PCR      Yes                 BsmI, AapI, TaqI
  Mahmoudi \[[@R28]\]         2010   Iran             Asian              160/180         52.6 ± 14.0     44.4 ± 17.6       PCR-RFLP     No                  AapI, TaqI
  Jenab \[[@R29]\]            2009   United Kingdom   Caucasian          1248/1248       58.5 ± 7.2      58.6 ± 7.2        Taqman       Yes                 FokI, BsmI
  Theodoratou \[[@R30]\]      2008   United Kingdom   Caucasian          3005/3072       62.0 ± 10.7     62.4 ± 10.5       Microarray   No                  FokI, BsmI, AapI, Cdx2
  Ochs-Balcom \[[@R31]\]      2008   United States    Mixed              250/246         62.7 ± 10.2     58.4 ± 12.1       Taqman       Yes                 FokI, TaqI, Cdx2
  Li \[[@R32]\]               2008   China            Asian              200/200         61.5 ± 12.6     61.3 ± 12.5       PCR-RFLP     Yes                 FokI, BsmI
  Parisi \[[@R33]\]           2008   Spain            Caucasian          50/32           NA              NA                PCR-RFLP     Yes                 BsmI
  Wang \[[@R34]\]             2008   China            Asian              60/218          38--78          19.6 ± 1.3        PCR-RFLP     Yes                 FokI
  Grünhage \[[@R35]\]         2008   Germany          Caucasian          194/220         65 ± 9          63 ± 8            PCR-RFLP     Yes                 FokI
  Flügge \[[@R36]\]           2007   Germany          Caucasian          256/256         61.9 ± 10.0     62.2 ± 11.2       PCR-RFLP     Yes                 FokI, BsmI, AapI, TaqI, Cdx2
  Slattery \[[@R37]\]         2007   United States    Caucasian          2380/2990       NA              NA                Taqman       Yes                 FokI, BsmI
  Yaylim-Eraltan \[[@R38]\]   2007   Turkey           Caucasian          26/52           59.1 ± 4.0      52.0 ± 0.8        PCR-RFLP     No                  FokI, TaqI
  Murtaugh \[[@R39]\]         2006   United States    Caucasian          1820/2821       NA              NA                PCR-RFLP     Yes                 FokI
  Kadiyska \[[@R40]\]         2006   Bulgaria         Caucasian          140/94          59 (22--83)     NA                PCR-RFLP     Yes                 BsmI
  Park \[[@R41]\]             2006   South Korea      Asian              190/318         55 (32--81)     NA                PCR-RFLP     Yes                 FokI, BsmI, AapI, TaqI
  Slattery \[[@R42]\]         2004   United States    Caucasian          1936/2130       NA              NA                PCR-RFLP     No                  FokI, BsmI
  Peters \[[@R43]\]           2004   United States    Caucasian          763/774         62.9            62.3              PCR-RFLP     Yes                 FokI
  Boyapati \[[@R44]\]         2003   United States    Caucasian          177/228         58.4 ± 8.4      56.0 ± 10.0       PCR-RFLP     No                  BsmI
  Wong \[[@R45]\]             2003   China            Asian              217/890         56.5            NA                PCR-RFLP     Yes                 FokI
  Peters \[[@R46]\]           2001   United States    Caucasian          239/228         NA              NA                PCR-RFLP     Yes                 FokI
  Ingles \[[@R47]\]           2001   United States    Caucasian          373/394         62.3            62.2              PCR-RFLP     Yes                 FokI
  Kim \[[@R48]\]              2001   United States    Caucasian          393/406         57.9 ± 9.7      53.0 ± 10.9       Taqman       Yes                 BsmI
  Slattery \[[@R49]\]         2001   United States    Caucasian          424/266         NA              NA                PCR-RFLP     Yes                 FokI, BsmI, TaqI

VDR, vitamin D receptor; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; ASM-PCR, allele specific multiple-PCR; HWE, Hardy--Weinberg equilibrium; NA, **Not available**.

Heterogeneity and publication bias {#s2_2}
----------------------------------

The heterogeneity was assessed for each study using the *Q* statistic. Significant heterogeneity (*P* for heterogeneity \< 0.10 or *I^2^* \> 50%) between studies were observed in *BsmI* and *ApaI*, but no heterogeneity was found in *FokI*, *TaqI* and *Cdx2* polymorphisms.

Funnel plot and Egger's test were performed to evaluate the publication bias of literatures on CRC, and no statistically significant publication biases were found in all genetic models.

Meta-analysis results {#s2_3}
---------------------

### FokI polymorphism and CRC {#s2_3_1}

A total of 29 studies examined the association between CRC and the *FokI* polymorphism. The result of meta-analysis showed that the *FokI* polymorphism was on the fringe of statistically significant in the comparison of F allele vs. f allele in fixed model (OR = 1.029, *95%CI* = 0.999--1.059, *P*^raw^ = 0.057, *P~FDR~ =* 0.057). The homozygous model, the dominant model and the recessive model were no significant associated with CRC risk (Table [2](#T2){ref-type="table"}).

###### Meta-analysis of the association between VDR polymorphisms and CRC

  SNP    Comparison       Qualified studies   OR (95%CI)             *P*-value   FDR         Heterogeneity test             Effect model
  ------ ---------------- ------------------- ---------------------- ----------- ----------- ------------------------------ --------------
  FokI   F vs. f          29                  1.029 (0.999--1.059)   0.057       0.057       *P* = 0.003, I*^2^* = 46.8%    F
         FF vs. ff                            1.055 (0.990--1.123)   0.097       0.211       *P* = 0.015, I*^2^* = 39.8%    F
         FF + Ff vs. ff                       1.045 (0.986--1.107)   0.141       0.211       *P* = 0.124, I*^2^* = 23.9%    F
         Ff + ff vs. FF                       0.974 (0.876--1.083)   0.625       0.625       *P* \< 0.001, I*^2^* = 81.5%   R
  BsmI   B vs. b          23                  0.862 (0.761--0.976)   0.019^\*^   0.019^\*^   *P* \< 0.001, I*^2^* = 91.4%   R
         BB vs.bb                             0.786 (0.636--0.972)   0.026^\*^   0.039^\*^   *P* \< 0.001, I*^2^* = 85.5%   R
         BB + Bb vs. bb                       0.824 (0.705--0.964)   0.015^\*^   0.039^\*^   *P* \< 0.001, I*^2^* = 88.0%   R
         Bb + bb vs. BB                       0.887 (0.759--1.036)   0.129       0.129       *P* \< 0.001, I*^2^* = 78.8%   R
  ApaI   A vs. a          12                  1.025 (0.928--1.132)   0.631       0.631       *P* \< 0.001, I*^2^* = 68.9%   R
         AA vs. aa                            0.953 (0.775--1.172)   0.650       0.900       *P* \< 0.001, I*^2^* = 67.9%   R
         AA + Aa vs. aa                       1.009 (0.875--1.163)   0.900       0.900       *P* = 0.003, I*^2^* = 59.8%    R
         Aa + aa vs. AA                       0.901 (0.770--1.055)   0.197       0.591       *P* = 0.001, I*^2^* = 65.5%    R
  TaqI   T vs. t          18                  1.011 (0.960--1.066)   0.673       0.673       *P* = 0.081, I*^2^* = 33.1%    F
         TT vs. tt                            1.027 (0.912--1.157)   0.656       0.746       *P* = 0.091, I*^2^* = 32.5%    F
         TT +Tt vs. tt                        1.018 (0.913--1.136)   0.746       0.746       *P* = 0.069, I*^2^* = 35.4%    F
         Tt + tt vs. TT                       1.013 (0.944--1.086)   0.724       0.746       *P* = 0.310, I*^2^* = 11.8%    F
  Cdx2   C vs. c          4                   0.936 (0.828--1.058)   0.287       0.287       *P* = 0.352, I*^2^* = 8.2%     F
         CC vs. cc                            0.862 (0.627--1.186)   0.363       0.544       *P* = 0.193, I*^2^* = 36.6%    F
         CC + Cc vs. cc                       0.933 (0.723--1.204)   0.594       0.594       *P* = 0.176, I*^2^* = 39.3%    F
         Cc + cc vs. CC                       0.918 (0.783--1.077)   0.293       0.544       *P* = 0.777, I*^2^* = 0.0%     F

VDR, vitamin D receptor; CRC, Colorectal cancer; OR, odds ratios; 95% CI, 95% confidence interval; FDR: *p* value from Benjamini--Hochberg method control for false discovery rate (FDR); R, random-effects model; F, fixed-effects model; ^\*^statistical significance.

### *BsmI* polymorphism and CRC {#s2_3_2}

There were 23 articles on the relationship between *BsmI* polymorphism and CRC. We observed significant differences in allele frequencies, the homozygous model and the dominant model between CRC patients and healthy controls (B vs. b: OR = 0.862, *95% CI* = 0.761--0.976, *P*~raw~ = 0.019, *P*~FDR~*=* 0.019; BB vs. bb: OR = 0.786, *95% CI* = 0.636--0.972, *P*~raw~ = 0.026, P~*FDR*~ *=* 0.039; BB + Bb vs. bb: OR = 0.824, *95% CI* = 0.705--0.964, *P*~raw~ = 0.015, *P*~FDR~ *=* 0.039, respectively). There was little evidence of significant differences that investigated an association between *BsmI* polymorphism and CRC in the recessive model (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

![Forest plots for *BsmI* gene polymorphism and CRC\
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Other polymorphisms and CRC {#s2_4}
---------------------------

Other three polymorphisms including *ApaI*, *TaqI*, *Cdx2* were not associated with CRC in all genetic models.

Sensitivity analysis {#s2_5}
--------------------

Sensitivity analysis was performed by sequential omission of individual studies. The pooled ORs of the polymorphisms were not altered after omission, indicating that our results were statistically robust.

DISCUSSION {#s3}
==========

The pathogenesis of CRC remains unknown. Gene-environment interactions, gene-gene interactions and life-style have an important impact on the development of CRC. There is consistent epidemiologic evidence that increased vitamin D intake is associated with reduced risk of colorectal. *VDR* mediate the biological activity of vitamin D and plays a crucial role in the etiology and development of cancer. A number of genetic associations studies were carried out to investigate the association of *VDR* polymorphisms with CRC risk, but the results are conflictive and the effect of *VDR* polymorphisms on CRC remains unclear. Therefore, in order to overcome the limitations of individual studies, we performed meta-analysis to evaluate the associations of *VDR* polymorphisms with CRC risk. Meta-analysis increases statistical power and resolution by pooling the results of independent analyses. A total of 52 reports had predicted a potential genetic association, and only 39 articles were included in this meta-analysis based on the selection criteria. The meta-analysis showed that the *FokI* polymorphism was on the fringe of statistically significant in the comparisons of F vs. f (OR = 1.029, *95% CI* = 0.999--1.059, *P~raw~* = 0.057, *P~FDR~ =* 0.057) and the *BsmI B* allele was associated with a lower CRC risk (B vs. b: OR = 0.862, *95% CI* = 0.761--0.976, *P~raw~* = 0.019, *P~FDR~* *=* 0.019). Similarly, a decreased CRC risk was also found in the homozygous model and the dominant model of *BsmI* (BB vs. bb: OR = 0.786, *95% CI* = 0.636--0.972, *P~raw~* = 0.026, *P~FDR~* *=* 0.039; BB + Bb vs. bb: OR = 0.824, *95% CI* = 0.705--0.964, *P~raw~* = 0.015, *P~FDR~* *=* 0.039, respectively). The results are consistent with the previous meta-analysis, which further confirmed the conclusions of the previous meta-analysis. However, our results were not consistent with the previous meta-analysis in the recessive model of *BsmI* and CRC. Yu et al. \[[@R3]\] and Bai et al. \[[@R51]\] draw the conclusion that the recessive model of *BsmI* was associated with a decreased CRC risk. The reasons for different results are as follows: first, our study is an updated and more carefully selected study than Yu et al and Bai et al. Second, our study included more Asian population. The estimated VDR polymorphisms including *FokI*, *ApaI*, *TaqI* and *Cdx2* showed no significant associations between CRC. Previous meta-analysis's pooled ORs were similar to ours. In addition, we found significant heterogeneities between studies in *BsmI* and *ApaI*. But the reasons for the heterogeneity were unclear. The heterogeneity may be explained by the following factors: the study design, clinical characteristics, year of publication, and especially the different genetic backgrounds.

As in any study, some limitations of this study should be considered. First, only published studies in English and Chinese were included in this meta-analysis, so publication bias may have occurred. Second, significant heterogeneity was observed in overall comparisons. Although no publication bias was observed, different background and variant adjusted factors of controls were possible major source of heterogeneity. Third, although environment and diet may partially contribute to CRC, gene-gene and gene-environment interactions could not be investigated. Fourth, meta-analysis was still an observational study that subjected to the methodological deficiencies of the included studies.

In conclusion, this meta-analysis suggests that *BsmI* was associated with CRC risk and *FokI* might be risk factors for CRC. However, these associations with CRC need further studied.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

All genetic association studies that assessed the associations of the *FokI*, *BsmI*, *ApaI*, *TaqI* and *Cdx2* polymorphisms in the *VDR* genes with CRC susceptibility were included/enrolled in the meta-analysis. The studies were identified by extended computer based search of The PubMed, Web of Science, the Chinese Biomedical Database (CBM) and Chinese National Knowledge Infrastructure (CNKI) and Wanfang (Chinese) databases (published until April 2017). The keywords "Colorectal cancer" or "CRC" or "Colorectal carcinoma" or "Colorectal tumor", "polymorphism" or "variant" or "genes" or "genotypes" or "genotyping", "vitamin D receptor" or "*VDR*" were used. All references cited in the publications were also reviewed to identify other relevant publications. Finally, only published studies with full text were included.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Regarding CRC susceptibility and *VDR* gene polymorphisms, studies which satisfy all the following criteria were identified: (1) articles investigate the associations of the *FokI*, *BsmI*, *ApaI*, *TaqI* and *Cdx2* polymorphisms in the *VDR* genes with the development of CRC; (2) a case--control study; (3) articles reported the number of individual genotypes and/or alleles for *VDR* polymorphisms in cases and controls; (4) the paper should clearly describe CRC diagnoses; (5) the control' ethnic background and geographic area were the same with case'; (6) the language of articles was restricted to English or Chinese; (7) full text was available. Exclusion criteria: (1) the study was conducted on animals; (2) abstracts, case reports, editorials and review articles were excluded; (3) studies that did not met the inclusion criteria; (4) study with no detailed data.

Data extraction {#s4_3}
---------------

According to the selection criteria, data from relevant studies were carefully and independently extracted by two authors (Zhipeng Pan and Mengya Chen). Disagreement was resolved by discussion and consultation with the third researcher (Xingxing Hu). The following data were extracted if available: first author, year of publication, country, ethnicity of study population, the genotyping method, sample size, number of each genotype in cases and controls.

Statistical analysis {#s4_4}
--------------------

The strength of the associations between the *VDR* polymorphisms and CRC susceptibility were evaluated by Odds ratios (ORs) with 95% confidence intervals (95% *CIs*) under the appropriate genetic model. The pooled ORs were calculated for the allele contrasts, homozygous model, recessive genetic model and dominant genetic model. *P* value \< 0.05 was considered to be statistically significant comparing CRC cases with controls. Considering the possibility of heterogeneity in the studies, heterogeneity assumption was measured by the chi-square based *Q* test (*P* \< 0.1 indicates heterogeneity) \[[@R52]\]. In addition, the presence of heterogeneity between studies was tested by the *I^2^*. *I^2^* values of 25, 50, and 75% are defined as low, moderate, and high estimates, respectively. The pooled effect was calculated by a fixed effect model when there is no heterogeneity (*I^2^* \< 50% or *P* \> 0.1), otherwise, a random effects model was used. HWE was assessed by the Chi-square test in the control group of each study in all the included studies (*P* \< 0.05 was considered significant). The funnel plot and Egger's regression test were used to search for publication bias, and an asymmetric Funnel plot or *P* \< 0.05 in Egger weighted regression suggested possible publication bias. In consideration of multiple comparisons, Benjamini--Hochberg (BH) method was applied to control the false discovery rate (FDR). All the statistical manipulations were performed using the STATA statistical software 11.0 (StataCorp, College Station, TX, USA) and Review Manager Software 5.1 (Cochrane Collaboration, Oxford, UK). All *P* values tested were two-tailed.
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